Results 11 to 20 of about 460,022 (246)

Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?

Hemato, 2022
Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM diagnosis and therapeutic strategy mainly rely on direct
Emilie Arnault Carneiro, Filipa Barahona, Carolina Pestana, Cristina João   +3 more
doaj   +1 more source

Cardiac Lymphoma

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 2018
[Abstract Not Available]
Cagli, Kumral, Dogru, Ceren Yagmur, Ozdemir, Mustafa, Turhan, Nesrin, Golbasi, Zehra   +4 more
openaire   +4 more sources

Lymphomas☆

, 2015
An unprecedented increase in lymphoma incidence has been observed over the past several decades. Recently, stabilization in incidence has been reported for some, but not all, lymphoma subtypes. In addition to subtype-specific differences in temporal trends, variation in demographic incidence patterns has been described.
van Leeuwen, MT, Vajdic, CM
openaire   +3 more sources

Effects of Cancer Treatment on Somatosensory and Nociceptive Processing in Children and Adolescents: A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Chemotherapy‐induced peripheral neuropathy remains a major complication in pediatric cancer, with disrupted somatosensory and nociceptive processing being a key aspect. This review synthesizes empirical studies on alterations in somatosensory and nociceptive processing in children and adolescents with cancer.
Julia Schweiger, Laura Walz, Michael C. Frühwald, Stefan Lautenbacher, Miriam Kunz   +4 more
wiley   +1 more source

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Haematologica, 2020
The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored.
Paolo Strati, Mohamed Amin Ahmed, Nathan H. Fowler, Loretta J. Nastoupil, Felipe Samaniego, Luis E. Fayad, Fredrick B. Hagemeister, Jorge E. Romaguera, Alma Rodriguez, Michael Wang, Jason R. Westin, Chan Cheah, Mansoor Noorani, Lei Feng, Richard E. Davis, Sattva S. Neelapu   +15 more
doaj   +1 more source

Exploring Preferences for a Digital Single‐Session Intervention for Adolescent Siblings of Youth With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Adolescent siblings of children with cancer are at elevated risk for psychosocial problems. Unfortunately, various barriers such as limited family time and resources, conflicting schedules, and psychosocial staffing constraints at cancer centers hinder sibling access to support.
Christina M. Amaro, Sarah Silver, Prishi Patel, Meredith K. Reffner Collins, Kimberly S. Canter, Stephanie Fooks‐Parker, Michael Amylon, Shawna V. Hudson, Jessica L. Schleider, Melissa A. Alderfer, Katie A. Devine   +10 more
wiley   +1 more source

Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma‐associated hemophagocytic lymphohistiocytosis: A multicenter analysis

Cancer Medicine
Background Lymphoma is the most common secondary cause of hemophagocytic lymphohistiocytosis (HLH) in adults. Lymphoma‐associated HLH (LA‐HLH) in the elderly population is not rare, however, little has been reported regarding clinicopathological ...
Yi Miao, Jing Zhang, Xuzhang Lu, Meng Wu, Bingzong Li, Liang Yu, Miao Sun, Yun Zhuang, Yuqing Miao, Haiwen Ni, Xiaoyan Xie, Jingyan Xu, Yunping Zhang, Min Zhao, Min Xu, Wanchuan Zhuang, Weiying Gu, Guoqiang Lin, Haiying Hua, Jianfeng Zhu, Maozhong Xu, Tao Jia, Ping Liu, Lijia Zhai, Tongtong Zhang, Qiurong Shan, Qiudan Shen, Jun Qian, Chunling Wang, Jianyong Li, Wenyu Shi   +30 more
doaj   +1 more source

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

Journal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang   +5 more
doaj   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Burkitt's Lymphoma [PDF]

New England Journal of Medicine, 1977
TWO decades have passed since Denis Burkitt, a British surgeon working in Uganda, originally described the tumor that now bears his name.1 The discovery that this tumor has distinctive clinical and...
openaire   +4 more sources